Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Vanguard Short Term Corporate Bond ETF — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B), while Vanguard Short Term Corporate Bond ETF trades at $77.3 (market cap $51.90B). The key difference: Vanguard Short Term Corporate Bond ETF is far larger — about 7.1× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Vanguard Short Term Corporate Bond ETF for 54 Days on average.
| SYRE | VCSH | |
|---|---|---|
Market Cap | $7.35B | $51.90B |
Volume | 1,624,631 | 12,465,005 |
Sector | Health | Fixed Income |
52-Week High | $108.92 | $80.20 |
52-Week Low | $22.18 | $77.03 |
Typical Hold Time | 0 Days | 54 Days |
Enterprise Value | $6.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
VCSH trades at $77.32, down 0.05% with a bearish technical signal. The ETF offers a competitive yield around 4.5% with a short 2.7-year duration, providing stability amid rising rates. Recent news highlights VCSH's lower expense ratio of 0.03% compared to peers and its focus on investment-grade corporate bonds. However, technical indicators show selling pressure with RSI at overbought levels and bearish moving average signals.
The outlook remains cautious due to tight credit spreads and limited price appreciation potential. While VCSH provides higher yield than treasury alternatives, it carries greater credit risk. Recent institutional activity shows mixed sentiment with both position increases and decreases reported. The ETF's short duration minimizes interest rate risk but faces headwinds from compressed spreads and competitive pressure from broader bond ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
